Related Experiment Video
Updated: Oct 2, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
CD38 a biomarker and therapeutic target in non-hematopoietic tumors
Susana G Barrientos-Robledo1, Jorge A Cebada-Ruiz1, Juan C Rodríguez-Alba2
1Laboratorio de Inmunología Experimental, Benemérita Universidad Autónoma de Puebla, Facultad de Medicina, Puebla, Mexico.
Abstract:
The type II transmembrane glycoprotein CD38 has recently been implicated in regulating metabolism and the pathogenesis of multiple conditions, including aging, inflammation and cancer. CD38 is overexpressed in several tumor cells and microenvironment tumoral cells, associated to migration, angiogenesis, cell invasion and progression of the disease. Thus, CD38 has been used as a progression marker for different cancer types as well as in immunotherapy. This review focuses on describing the involvement of CD38 in various non-hematopoietic cancers.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
lncRNA - Long Non-coding RNAs

